Appendix B: Drug Characteristics Tables

Characteristics of the Fusion Inhibitor

Appendix B, Table 7. Characteristics of the Fusion Inhibitor
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendation Serum Half-Life Elimination Adverse Eventsa
Enfuvirtide
(T-20)
Fuzeon
Fuzeon:
  • Injectable; supplied as lyophilized powder.
  • Each vial contains 108 mg of T-20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
  • Refer to prescribing information for storage instruction.
Fuzeon:
  • T-20 90 mg/1 mL SQ twice daily
3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients

Increased incidence of bacterial pneumonia

HSR occurs in <1% of patients. Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
a Also see Table 17.

Key: HSR = hypersensitivity reaction; SQ = subcutaneous; T-20 = enfuvirtide

Appendix B: Drug Characteristics Tables

Characteristics of the Fusion Inhibitor

Appendix B, Table 7. Characteristics of the Fusion Inhibitor
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendation Serum Half-Life Elimination Adverse Eventsa
Enfuvirtide
(T-20)
Fuzeon
Fuzeon:
  • Injectable; supplied as lyophilized powder.
  • Each vial contains 108 mg of T-20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
  • Refer to prescribing information for storage instruction.
Fuzeon:
  • T-20 90 mg/1 mL SQ twice daily
3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients

Increased incidence of bacterial pneumonia

HSR occurs in <1% of patients. Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
a Also see Table 17.

Key: HSR = hypersensitivity reaction; SQ = subcutaneous; T-20 = enfuvirtide
Updated
Reviewed
Dec. 18, 2019

Download Guidelines